Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
RedirecTT-1: Talquetamab + Teclistamab in Relapsed or Refractory Multiple Myeloma
jRCT2031230640Phase 2Active, not recruiting
- Sponsor
- Janssen Pharmaceutical
- Start
- Mar 2024
- Modality
- T-cell Engagers → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics, Bispecific Antibodies → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics, Monoclonal Antibodies → Antibody-Based Therapeutics
01
Overview
Phase 2, open-label trial of talquetamab and teclistamab in multiple myeloma (MM) (3 arms), sponsored by Janssen Pharmaceutical. Primary endpoints: Part 1: Number of Participants with Dose Limiting Toxicity (DLT), Part 1: Severity of Dose Limiting Toxicity (DLT) by NCI-CTCAE and 3 more. Started Mar 2024; status: active, not recruiting.
02
Drugs
talquetamabteclistamab
03
Conditions
multiple myeloma (MM)
Beyond the preview
Go deeper on jRCT2031230640.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2031230640.